Navigation Links
Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
Date:4/30/2013

JACKSONVILLE, Fla. Researchers at Mayo Clinic's campus in Florida have discovered a protein that is overly active in every human sample of kidney cancer they examined. They also found that an experimental drug designed to block the protein's activity significantly reduced tumor growth in animals when used alone. Combining it with another drug already used to treat the cancer improved the effectiveness of both.

The findings, reported in the April 30 online issue of Clinical Cancer Research, offer a much-needed potential new direction for the treatment of clear cell renal cell carcinoma, which accounts for almost 85 percent of kidney cancer cases in the United States. More than 57,000 diagnoses of kidney cancer occur yearly in the U.S. with greater than 13,000 deaths.

"There is a clear need for new therapies for this common cancer. With very few exceptions, patients inevitably become resistant to all available treatments," says the study's senior investigator, molecular biologist John Copland, Ph.D.

Their findings might be relevant to the treatment of other cancers, says Christina von Roemeling, the study's lead author. The protein they identified is produced by the stearoyl CoA desaturase 1 (SCD1) gene, which has also been found to be over active in a number of other cancers, including lung, stomach, breast, prostate, ovary and colon cancers.


'/>"/>
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Experts discuss ways to embed patient voices and values in clinical research
2. Trinity Health Selects Explorys’ Big Data Analytics Platform to Support Clinical Integration and Quality Initiatives
3. Cleveland Clinic research shows Internet-based program effective in reducing stress
4. Cloud Computing in Pharmaceutical Research and Development - Virtualization of Data through the Cloud Optimizes Next-Generation DNA Sequencing and Clinical Trials Data
5. Contract Research Organization WCCT Global Announces Overwhelming Success of Pediatric Clinical Study Recruitment
6. Mayo Clinic creates institution-wide electronic prolonged QT interval warning system
7. Sickle cell project named among Top 10 Clinical Research Achievements for 2012
8. Illinois-based OSF HealthCare joins Mayo Clinic Care Network
9. Cleveland Clinic Childrens Hospital research suggests transmission of respiratory viruses in utero
10. Clinical Trials Helped One Womans Fight Against Cancer
11. National awards celebrate clinical research achievements in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... NC (PRWEB) May 04, 2015 ... provider created a stir and showed the healthcare ... a major healthcare procedure, the downside of balance ... of a healthcare provider billing a patient for ... chooses to reimburse and what the provider chooses ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Hinds, Eric Gladen’s documentary Trace Amounts, and Allison Folmar, ... annual autism conference held internationally. , On Sunday, May ... Is recovery from autism possible?" Are you interested in ... You’re In There: winning our war against autism ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Women’s ... their Facebook page. , Their Facebook page ... many services the Practice has, it’s multiple locations, Providers ... Women’s Excellence has a very strong social media presence, ... and You Tube. , Women’s Excellence is the ...
Breaking Medicine News(10 mins):Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
... , WASHINGTON, July 22 The ... Tobacco-Free Kids: , , The U.S. ... so-called electronic cigarettes by seeking to block importation of these products ... potential health risks of these products. The FDA announced today ...
... , PORTLAND, Ore., July 22 For ... originally created and produced videos developed for myRegence.com , a health ... The 30th Annual Telly Awards are widely considered to be ... from more than 14,000 entries worldwide. , , ...
... , , OWINGS MILLS, Md., July 22 ... MED ), our Directors, Employees and Associates are delighted that ... been nominated by President Obama, and confirmed by the U.S. Senate, as ... , Gen. McCarthy has served his country in ...
... SAN DIEGO, July 22 Orexigen Therapeutics, Inc. (Nasdaq: ... market and other conditions, 9,000,000 shares of its common stock in ... to grant to the underwriter a 30-day option to purchase up ... if any. All of the shares are being offered by Orexigen. ...
... , , MENLO PARK, Calif., July ... results for the second quarter ended July 3, 2009. , ... revenues increased 11% to $60,862,000, as compared to $54,956,000 in the second ... as compared to $50,801,000 in the second quarter of 2008. Net ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 3Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 3Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Exponent Reports Second Quarter 2009 Results 2Health News:Exponent Reports Second Quarter 2009 Results 3Health News:Exponent Reports Second Quarter 2009 Results 4Health News:Exponent Reports Second Quarter 2009 Results 5Health News:Exponent Reports Second Quarter 2009 Results 6Health News:Exponent Reports Second Quarter 2009 Results 7Health News:Exponent Reports Second Quarter 2009 Results 8Health News:Exponent Reports Second Quarter 2009 Results 9
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
Medicine Products: